Entecavir resistance in chronic hepatitis B patients
Part of Digestive system, Infections clinical trials.
This study looks at whether hepatitis B virus becomes resistant to a drug called entecavir in people in Turkey. It may help doctors understand why some people's treatment stops working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have chronic hepatitis B (a long-term infection that affects the liver)
- You must not have taken entecavir or telbivudine before
- You must have never been treated for hepatitis B and have a high viral load, OR you must have taken lamivudine for at least 6 months and then switched to adefovir, tenofovir, or TAF
- You must be able to agree to participate in the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how to best use existing hepatitis B “nucleotide-analog” tablets in everyday care. It may help tailor when to start, and whether to continue or adjust treatment, based on your test results.
This study tests a new antibody treatment (VIR-3434) for chronic hepatitis B. It aims to see if the antibody can help your immune system control the virus, potentially allowing you to stop your current antiviral medication later.
This study looks at why some people with chronic hepatitis B develop resistance to antiviral medications. It may help doctors choose better treatments for patients taking tenofovir, entecavir, or lamivudine.
This study compares two approved hepatitis B medicines—tenofovir alafenamide and entecavir—to see which works best for people with chronic hepatitis B. It may help improve control of the virus and support better long-term liver health.
This study compares two treatments for children aged 3 to 6 with chronic hepatitis B. One group gets the standard medicine entecavir, and the other gets entecavir plus a medicine that helps the immune system fight the virus (peginterferon). The goal is to see if the combination works better.
This study tests two daily doses of the medicine entecavir to see which one better controls the hepatitis B virus in people with advanced liver scarring (cirrhosis). It aims to find the most effective dose to improve liver health.
Hear when a new Hepatitis B, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.